James Stannah1, Elizabeth Dale1, Jocelyn Elmes2, Roisin Staunton1, Chris Beyrer3, Kate M Mitchell4, Marie-Claude Boily5. 1. Medical Research Council Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London, UK. 2. Department of Public Health, Environments and Society, London School of Hygiene and Tropical Medicine, London, UK. 3. Center for Public Health and Human Rights, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MA, USA. 4. Medical Research Council Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London, UK; HIV Prevention Trials Network Modelling Centre, Imperial College London, London, UK. 5. Medical Research Council Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London, UK; HIV Prevention Trials Network Modelling Centre, Imperial College London, London, UK. Electronic address: mc.boily@imperial.ac.uk.
Abstract
BACKGROUND: HIV disproportionately affects gay, bisexual, and other men who have sex with men (MSM) in Africa, where many countries criminalise same-sex behaviour. We assessed changes in the engagement of African MSM with HIV testing and treatment cascade stages over time, and the effect of anti-LGBT legislation and stigma. METHODS: We systematically searched Embase, Global Health, MEDLINE, Scopus, and Web of Science for peer-reviewed cross-sectional or longitudinal studies recruiting at least ten MSM, published from Jan 1, 1980, to Oct 10, 2018. We extracted or derived estimates of HIV testing, engagement with the HIV treatment cascade, or both among African MSM from published reports. We derived pooled estimates using inverse-variance random-effects models. We used subgroup and meta-regression analysis to assess associations between testing and status awareness outcomes and study and participant characteristics, including the severity of country-level anti-LGBT legislation. FINDINGS: Our searches identified 75 independent eligible studies that provided estimates for 44 993 MSM across one or more of five testing and treatment cascade outcomes. HIV testing increased significantly over time overall, with pooled proportions of MSM ever tested for HIV of 67·3% (95% CI 62·1-72·3; 44 estimates) and tested in the past 12 months of 50·1% (42·4-57·8, 31 estimates) after 2011, which were 14·8 percentage points and 17·9 percentage points higher than before 2011, respectively. After 2011, ever testing was highest in southern Africa (80·0%), and lowest in northern Africa (34·4%), with the greatest increase in western Africa (from 42·4% to 70·9%). Levels of testing ever, in the past 12 months, and status awareness were statistically significantly lower in countries with the most severe anti-LGBT legislation compared with countries with the least severe legislation (57·4% vs 71·6%, p=0·0056; 35·5% vs 49·3%, p=0·010; 6·7% vs 22·0%, p=0·0050). Few estimates were available for later stages of the treatment cascade. Available data after 2011 suggest that the pooled proportion of MSM HIV-positive aware has remained low (18·5%, 12·5-25·3; 28 estimates), whereas proportions of current antiretroviral therapy (ART) use were 23·7% (15·5-33·0; 13 estimates) among all MSM living with HIV and 60·1% (48·6-71·1; five estimates) among MSM HIV-positive aware of their status. Pooled levels of viral suppression among MSM currently on ART were 75·6% (64·4-85·5; four estimates), but only 24·7% (18·8-31·2; four estimates) among all MSM living with HIV. INTERPRETATION: Despite improvements in HIV testing among MSM in Africa, HIV status awareness, ART coverage, and viral suppression remain much lower than required to achieve UNAIDS 90-90-90 targets. Further studies are urgently needed to provide more accurate estimates of levels of status awareness, engagement in care, ART coverage, and viral suppression among MSM to inform prevention efforts aimed at improving access to HIV services for MSM. Severe anti-LGBT legislation might be associated with lower HIV testing and status awareness; therefore, further research is needed to assess the effect of such legislation on HIV testing and engagement with the HIV treatment cascade among MSM. FUNDING: US National Institutes of Health, UK Medical Research Council.
BACKGROUND: HIV disproportionately affects gay, bisexual, and other men who have sex with men (MSM) in Africa, where many countries criminalise same-sex behaviour. We assessed changes in the engagement of African MSM with HIV testing and treatment cascade stages over time, and the effect of anti-LGBT legislation and stigma. METHODS: We systematically searched Embase, Global Health, MEDLINE, Scopus, and Web of Science for peer-reviewed cross-sectional or longitudinal studies recruiting at least ten MSM, published from Jan 1, 1980, to Oct 10, 2018. We extracted or derived estimates of HIV testing, engagement with the HIV treatment cascade, or both among African MSM from published reports. We derived pooled estimates using inverse-variance random-effects models. We used subgroup and meta-regression analysis to assess associations between testing and status awareness outcomes and study and participant characteristics, including the severity of country-level anti-LGBT legislation. FINDINGS: Our searches identified 75 independent eligible studies that provided estimates for 44 993 MSM across one or more of five testing and treatment cascade outcomes. HIV testing increased significantly over time overall, with pooled proportions of MSM ever tested for HIV of 67·3% (95% CI 62·1-72·3; 44 estimates) and tested in the past 12 months of 50·1% (42·4-57·8, 31 estimates) after 2011, which were 14·8 percentage points and 17·9 percentage points higher than before 2011, respectively. After 2011, ever testing was highest in southern Africa (80·0%), and lowest in northern Africa (34·4%), with the greatest increase in western Africa (from 42·4% to 70·9%). Levels of testing ever, in the past 12 months, and status awareness were statistically significantly lower in countries with the most severe anti-LGBT legislation compared with countries with the least severe legislation (57·4% vs 71·6%, p=0·0056; 35·5% vs 49·3%, p=0·010; 6·7% vs 22·0%, p=0·0050). Few estimates were available for later stages of the treatment cascade. Available data after 2011 suggest that the pooled proportion of MSM HIV-positive aware has remained low (18·5%, 12·5-25·3; 28 estimates), whereas proportions of current antiretroviral therapy (ART) use were 23·7% (15·5-33·0; 13 estimates) among all MSM living with HIV and 60·1% (48·6-71·1; five estimates) among MSM HIV-positive aware of their status. Pooled levels of viral suppression among MSM currently on ART were 75·6% (64·4-85·5; four estimates), but only 24·7% (18·8-31·2; four estimates) among all MSM living with HIV. INTERPRETATION: Despite improvements in HIV testing among MSM in Africa, HIV status awareness, ART coverage, and viral suppression remain much lower than required to achieve UNAIDS 90-90-90 targets. Further studies are urgently needed to provide more accurate estimates of levels of status awareness, engagement in care, ART coverage, and viral suppression among MSM to inform prevention efforts aimed at improving access to HIV services for MSM. Severe anti-LGBT legislation might be associated with lower HIV testing and status awareness; therefore, further research is needed to assess the effect of such legislation on HIV testing and engagement with the HIV treatment cascade among MSM. FUNDING: US National Institutes of Health, UK Medical Research Council.
Authors: Sara H Goodman; Ashley L Grosso; Sosthenes C Ketende; Gautier H Ouedraogo; Seni Kouanda; Odette Ky-Zerbo; Césaire Samadoulougou; Stefan Baral Journal: Sex Transm Dis Date: 2016-05 Impact factor: 2.830
Authors: Sheree R Schwartz; Rebecca G Nowak; Ifeanyi Orazulike; Babajide Keshinro; Julie Ake; Sara Kennedy; Ogbonnaya Njoku; William A Blattner; Manhattan E Charurat; Stefan D Baral Journal: Lancet HIV Date: 2015-07 Impact factor: 12.767
Authors: Andrea L Wirtz; Gift Trapence; Dunker Kamba; Victor Gama; Rodney Chalera; Vincent Jumbe; Rosemary Kumwenda; Marriam Mangochi; Stephane Helleringer; Chris Beyrer; Stefan Baral Journal: Lancet HIV Date: 2017-02-28 Impact factor: 12.767
Authors: Claire E Holland; Seni Kouanda; Marcel Lougué; Vincent Palokinam Pitche; Sheree Schwartz; Simplice Anato; Henri Gautier Ouedraogo; Jules Tchalla; Clarence S Yah; Laurent Kapesa; Sosthenes Ketende; Chris Beyrer; Stefan Baral Journal: Public Health Rep Date: 2016-11-14 Impact factor: 2.792
Authors: Wolfgang Hladik; Joseph Barker; John M Ssenkusu; Alex Opio; Jordan W Tappero; Avi Hakim; David Serwadda Journal: PLoS One Date: 2012-05-31 Impact factor: 3.240
Authors: Sameer Kushwaha; Yasmin Lalani; Geoffrey Maina; Adedotun Ogunbajo; Leo Wilton; Thomas Agyarko-Poku; Yaw Adu-Sarkodie; Francis Boakye; Nanhua Zhang; LaRon E Nelson Journal: BMC Public Health Date: 2017-10-03 Impact factor: 3.295
Authors: Michael E Herce; William M Miller; Agatha Bula; Jessie K Edwards; Pedro Sapalalo; Kathryn E Lancaster; Innocent Mofolo; Maria Lúcia M Furtado; Sharon S Weir Journal: J Int AIDS Soc Date: 2018-07 Impact factor: 5.396
Authors: LaRon E Nelson; Adedotun Ogunbajo; Gamji Rabiu Abu-Ba'are; Donaldson F Conserve; Leo Wilton; Jackson Junior Ndenkeh; Paula Braitstein; Dorothy Dow; Renata Arrington-Sanders; Patrick Appiah; Joe Tucker; Soohyun Nam; Robert Garofalo Journal: AIDS Behav Date: 2022-08-10
Authors: Paul Y Wada; Ahra Kim; Karu Jayathilake; Stephany N Duda; Yao Abo; Keri N Althoff; Morna Cornell; Beverly Musick; Steve Brown; Annette H Sohn; Yu Jiun Chan; Kara K Wools-Kaloustian; Denis Nash; Constantin T Yiannoutsos; Carina Cesar; Catherine C McGowan; Peter F Rebeiro Journal: AIDS Patient Care STDS Date: 2022-08-26 Impact factor: 5.944
Authors: John Mark Wiginton; Sarah M Murray; Jura Augustinavicius; Jessica L Maksut; Bridget J Anderson; Kwa Sey; Yingbo Ma; Colin P Flynn; Danielle German; Emily Higgins; Timothy W Menza; E Roberto Orellana; Anna B Flynn; Alia Al-Tayyib; Jennifer Kienzle; Garrett Shields; Zaida Lopez; Paige Wermuth; Stefan D Baral Journal: Am J Epidemiol Date: 2022-01-01 Impact factor: 5.363
Authors: Mariya V Sivay; Philip J Palumbo; Yinfeng Zhang; Vanessa Cummings; Xu Guo; Erica L Hamilton; Laura McKinstry; Arthur Ogendo; Noel Kayange; Ravindre Panchia; Karen Dominguez; Ying Q Chen; Theodorus G M Sandfort; Susan H Eshleman Journal: Clin Infect Dis Date: 2021-07-01 Impact factor: 9.079
Authors: Elizabeth Fearon; Siyanda Tenza; Cecilia Mokoena; Kerushini Moodley; Adrian D Smith; Adam Bourne; Peter Weatherburn; Thesla Palanee-Phillips Journal: PLoS One Date: 2020-06-17 Impact factor: 3.240
Authors: Maartje Dijkstra; Khamisi Mohamed; Alex Kigoro; Teresia Mumba; Shally Mahmoud; Abdalla Wesonga; Nana Mukuria; Tony Oduor; Evans Gichuru; Maarten F Schim van der Loeff; Shaun Palmer; Susan M Graham; Elise M van der Elst; Eduard J Sanders Journal: Open Forum Infect Dis Date: 2021-04-29 Impact factor: 3.835
Authors: Keith J Horvath; Teresa Walker; Linda Mireles; Jose A Bauermeister; Lisa Hightow-Weidman; Rob Stephenson Journal: Curr HIV/AIDS Rep Date: 2020-08 Impact factor: 5.495
Authors: Jean Olivier Twahirwa Rwema; Carrie E Lyons; Sara Herbst; Benjamin Liestman; Julien Nyombayire; Sosthenes Ketende; Amelia Mazzei; Oluwasolape Olawore; Sabin Nsanzimana; Placidie Mugwaneza; Aflodis Kagaba; Patrick S Sullivan; Susan Allen; Etienne Karita; Stefan D Baral Journal: J Int AIDS Soc Date: 2020-10 Impact factor: 5.396